04/06/2024 Tolvaptan for treating autosomal dominant polycystic kidney disease
NRThe Ministry of Health’s Drug Advisory Committee has not recommended tolvaptan for inclusion on the MOH List of Subsidised Drugs for treating autosomal dominant polycystic kidney disease (ADPKD). The decision was based on the uncertain extent of clinical benefit, and because tolvaptan was unlikely to represent a cost-effective use of healthcare resources for treating ADPKD.